Calls for papers
-
Neurelis says that it has received guidance from the FDA regarding clinical trial requirements for the company’s NRL-1 intranasal diazepam for the treatment of acute repetitive seizures in epilepsy patients and is now initiating the… Read more . . .
-
Turing Pharmaceuticals said that it has received a no objection letter from Health Canada regarding the initiation of Phase 1 trials of TUR-002 intranasal ketamine for the reduction of suicidal ideations and that it expects… Read more . . .
-
Acerus Pharmaceuticals has received approval from Health Canada to market Natesto nasal gel as a testosterone replacement therapy in adult males with hypogonadism, and the product should be available in Canada by mid-2016, the company… Read more . . .
-
Mylan submitted an abbreviated new drug application (ANDA) to the FDA for its fluticasone propionate/salmeterol DPI, a generic version of GSK’s Advair Diskus, for the treatment of asthma and COPD in December 2015, the company… Read more . . .
-
Particle engineering specialist Liquidia Technologies announced that it has hired Jason Adair as VP, Business Development & Strategy. Adair was most recently Executive Director of Corporate Development at BioCryst and was previously Director of Business… Read more . . .
-
MannKind Corporation has appointed Matthew J. Pfeffer as CEO effective January 10, 2016, replacing Alfred Mann. In November 2015, Mann temporarily resumed his role as CEO after Hakan Edstrom stepped down. On January 5, 2016,… Read more . . .
-
Theravance, Inc, which spun off from Theravance Biopharma in 2013, will now be known as “Innoviva” and will trade on NASDAQ under the symbol “INVA,” the company said. Innoviva is partnered with GSK on the… Read more . . .
-
Vectura Group has confirmed that its US partner for the VR315 fluticasone/salmeterol DPI and the VR506 generic fluticasone propionate DPI is Boehringer Ingelheim subsidiary Roxane Laboratories. The company is partnered with Sandoz on VR315 in… Read more . . .
-
Swedish DPI developer Simplified Solutions announced that it has entered into an agreement with CSP Technologies for continued development of its X-haler dry powder inhaler through to commercial manufacturing. The credit-card sized multi-dose DPI will… Read more . . .
-
Qualcomm subsidiary Qualcomm Life will design a disposable module for the Breezhaler DPI that will sense and report inhaler usage data for Novartis’s Breezhaler COPD products, including Ultibro, Seebri, and Onbrez. The Breezhaler DPIs are… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland